help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Z. L.
Right arrow Articles by Bloom, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Z. L.
Right arrow Articles by Bloom, S. R.

Endocrinology, Vol 135, 200-206, Copyright © 1994 by Endocrine Society

ARTICLES

Evidence of a paracrine role of neuropeptide-Y in the regulation of insulin release from pancreatic islets of normal and dexamethasone- treated rats

ZL Wang, WM Bennet, RM Wang, MA Ghatei and SR Bloom
Department of Medicine, Royal Postgraduate Medical School, London, United Kingdom.

Recent evidence suggests that a number of a paracrine regulatory peptides, including neuropeptide-Y (NPY), are synthesized within pancreatic islets. We have, therefore, assessed the role of NPY on insulin release from isolated perifused rat islets. NPY release was detectable at 2.1 (95% confidence interval, 1.6-2.6) attomoles/islet.min from the perifused islets of control rats when the glucose concentration was 2.8 mM and decreased by 62% (P = 0.01) on changing to 20 mM glucose. The initial insulin release was 0.7 (0.3- 1.6) fmol/islet.min, and it was increased 4-fold (P < 0.001) by high glucose. Simultaneously, pancreatic glucagon release was decreased 85% (P < 0.001), and somatostatin release was decreased 25% (P = 0.06). In contrast, in islets from rats given dexamethasone (4 mg/kg.day) for 10 days, NPY release was 6-fold increased by high glucose. NPY (100 nM) decreased insulin release by 44% (P < 0.001). To determine the influence of naturally present islet NPY on insulin release, immunoneutralization with NPY antiserum was employed. With control rat islets, insulin release was increased 3-fold with NPY antiserum (P = 0.02) in the presence of 2.8 mM glucose and elevated 2-fold at 8 mM glucose (P < 0.001). NPY immunoneutralization similarly increased insulin release from the perifused islets of rats treated with dexamethasone. Our results suggest that NPY is produced by pancreatic islets, and its expression is dependent on the prevailing endocrine environment. Islet NPY appears to constrain insulin release under a variety of conditions. NPY may be an important intraislet paracrine hormone.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
Y. Imai, H. R. Patel, E. J. Hawkins, N. M. Doliba, F. M. Matschinsky, and R. S. Ahima
Insulin Secretion Is Increased in Pancreatic Islets of Neuropeptide Y-Deficient Mice
Endocrinology, December 1, 2007; 148(12): 5716 - 5723.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. Ma, S. Nordman, A. Mollsten, H. Falhammar, K. Brismar, G. Dahlquist, S. Efendic, and H. F Gu
Distribution of neuropeptide Y Leu7Pro polymorphism in patients with type 1 diabetes and diabetic nephropathy among Swedish and American populations
Eur. J. Endocrinol., November 1, 2007; 157(5): 641 - 645.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. M. Kamiji and A. Inui
Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity
Endocr. Rev., October 1, 2007; 28(6): 664 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Gao, L. Ghibaudi, and J. J. Hwa
Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms
Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E706 - E711.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. C. Reubi, M. Gugger, B. Waser, and J.-C. Schaer
Y1-Mediated Effect of Neuropeptide Y in Cancer: Breast Carcinomas as Targets
Cancer Res., June 1, 2001; 61(11): 4636 - 4641.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. C. Michel, A. Beck-Sickinger, H. Cox, H. N. Doods, H. Herzog, D. Larhammar, R. Quirion, T. Schwartz, and T. Westfall
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
Pharmacol. Rev., March 1, 1998; 50(1): 143 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Waeber, T. Calandra, R. Roduit, J.-A. Haefliger, C. Bonny, N. Thompson, B. Thorens, E. Temler, A. Meinhardt, M. Bacher, et al.
Insulin secretion is regulated by the glucose-dependent production of islet beta  cell macrophage migration inhibitory factor
PNAS, April 29, 1997; 94(9): 4782 - 4787.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Gremlich, R. Roduit, and B. Thorens
Dexamethasone Induces Posttranslational Degradation of GLUT2 and Inhibition of Insulin Secretion in Isolated Pancreatic beta Cells. COMPARISON WITH THE EFFECTS OF FATTY ACIDS
J. Biol. Chem., February 7, 1997; 272(6): 3216 - 3222.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society